PDF(Sci-hub)
Abstract：
Tumor recurrence after surgery is the main cause of treatment failure. However, the initial stage of recurrence is not easy to detect, and it is difficult to cure in the late stage. In order to improve the life quality of postoperative patients, an efficient synergistic immunotherapy was developed to achieve early diagnosis and treatment of post-surgical tumor recurrence, simultaneously. In this paper, two kinds of theranostic agents based on gold nanorods (AuNRs) platform were prepared. AuNRs and quantum dots (QDs) in one agent was used for the detection of carcinoembryonic antigen (CEA), using fluorescence resonance energy transfer (FRET) technology to indicate the occurrence of in situ recurrence, while AuNRs in the other agent was used for photothermal therapy (PTT), together with anti-PDL1 mediated immunotherapy to alleviate the process of tumor metastasis. A series of assays indicated that this synergistic immunotherapy could induce tumor cell death and the increased generation of CD3+/CD4+ T-lymphocytes and CD3+/CD8+ T-lymphocytes. Besides, more immune factors (IL-2, IL-6, and IFN-γ) produced by synergistic immunotherapy were secreted than mono-immunotherapy. This cooperative immunotherapy strategy could be utilized for diagnosis and treatment of postoperative tumor recurrence at the same time, providing a new perspective for basic and clinical research.
摘要：
肿瘤术后复发是导致治疗失败的主要原因。然而,复发的初始阶段不容易发现，后期很难治愈。为了提高术后患者的生活质量,开发了一种有效的协同免疫疗法，以实现对手术后肿瘤复发的早期诊断和治疗，同时。在本文中,制备了两种基于金纳米棒(AuNRs)平台的治疗剂。一种试剂中的AuNRs和量子点（QDs）用于检测癌胚抗原（CEA），使用荧光共振能量转移（FRET）技术来指示原位复发的发生，而另一种药物中的AuNRs用于光热治疗（PTT），与抗PDL1介导的免疫治疗一起缓解肿瘤转移的过程。一系列试验表明，这种协同免疫疗法可以诱导肿瘤细胞死亡和CD3+/CD4+T淋巴细胞和CD3+/CD8+T淋巴细胞的产生增加。此外,与单一免疫疗法相比,协同免疫疗法分泌的免疫因子(IL-2,IL-6和IFN-γ)更多.这种协同的免疫治疗策略可以同时用于肿瘤术后复发的诊断和治疗。为基础和临床研究提供了新的视角。
